title: Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases.
abstract: OBJECTIVE
  Methasteron is a nutritional supplement used to increase weight or accelerate the build-up of muscle mass. The aim of this study was to describe 5 cases of hepatotoxicity in patients using methasteron seen at tertiary-care medical centers.
  
  
  METHODS
  A case report design was used.
  
  
  RESULTS
  Five previously healthy patients who used methasteron developed jaundice 2 weeks after discontinuation; they presented to a tertiary-care medical center 2 weeks later. Within another 2 to 3 weeks, bilirubin levels peaked. About 12 weeks after initial presentation, all cases resolved with no identifiable residual hepatic dysfunction.
  
  
  CONCLUSIONS
  Methasteron use can result in severe hepatotoxicity. Liver failure can worsen after initial presentation, especially within 2 weeks. With close observation and supportive care, acute hepatic injury should resolve.
authors.affiliation: Department of Gastroenterology, Lahey Clinic Medical Center, Burlington, Massachusetts 01805, USA.
authors.forename: Neeral L
authors.initials: NL
authors.lastname: Shah
authors.forename: Isabel
authors.initials: I
authors.lastname: Zacharias
authors.forename: Urmila
authors.initials: U
authors.lastname: Khettry
authors.forename: Nezam
authors.initials: N
authors.lastname: Afdhal
authors.forename: Fredric D
authors.initials: FD
authors.lastname: Gordon
mesh_terms: D000328:Adult; D001663:Bilirubin / Q000097:blood; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced* / Q000150:complications*; D019587:Dietary Supplements / Q000009:adverse effects*; D006801:Humans; D041781:Jaundice, Obstructive / Q000139:chemically induced / Q000175:diagnosis; D008107:Liver Diseases / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D008297:Male
chemical_list: D001663:Bilirubin